Verastem, Inc. (LON:0LOV)
7.89
-1.93 (-19.67%)
At close: Nov 4, 2025
Verastem Revenue
Verastem had revenue of $11.24M USD in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $13.38M, up 33.79% year-over-year. In the year 2024, Verastem had annual revenue of $10.00M.
Revenue (ttm)
$13.38M
Revenue Growth
+33.79%
P/S Ratio
37.49
Revenue / Employee
$171.53K
Employees
78
Market Cap
373.15M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
| Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
| Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Verastem News
- 8 days ago - 3 Cancer-Focused Stocks Showing Strong Pipeline Progress - Nasdaq
- 13 days ago - Verastem (VSTM) Reveals Promising Early Results from VS-7375 Clinical Trial - GuruFocus
- 13 days ago - Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors - Business Wire
- 13 days ago - Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Nasdaq
- 13 days ago - Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 - Business Wire
- 16 days ago - Verastem (VSTM) Remains Strong Despite Recent Drop in Share Price - GuruFocus
- 16 days ago - Verastem (VSTM) Announces Promising Results from KRAS G12D Inhibitor Study - GuruFocus
- 16 days ago - Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice - Nasdaq